Dare Bioscience Files 8-K on Financials
Ticker: DARE · Form: 8-K · Filed: Mar 31, 2025 · CIK: 1401914
Sentiment: neutral
Topics: financial-condition, financial-statements, corporate-history
TL;DR
Dare Bioscience dropped its Q1 2025 financials on 8-K. Check it out.
AI Summary
Dare Bioscience, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122. The company was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
Why It Matters
This 8-K filing provides investors with an update on Dare Bioscience's financial performance and condition as of March 31, 2025.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any unusual risks.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- March 31, 2025 (date) — Date of Report
- 3655 Nobel Drive, Suite 260, San Diego, CA 92122 (location) — Principal Executive Offices
- Cerulean Pharma Inc. (company) — Former Company Name
- Tempo Pharmaceuticals Inc (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Dare Bioscience, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 31, 2025.
What is Dare Bioscience, Inc.'s principal executive office address?
Dare Bioscience, Inc.'s principal executive office is located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
What were Dare Bioscience, Inc.'s former company names?
Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
What is the Standard Industrial Classification code for Dare Bioscience, Inc.?
The Standard Industrial Classification code for Dare Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding Dare Bioscience, Inc. (DARE).